Beneficial effect of enalapril in spontaneously hypertensive rats cardiac remodeling with nitric oxide synthesis blockade

Journal of Cellular and Molecular Medicine

Volumn 6, Issue 4, 2002, Pages 599-608

  Zorzi, R L De Andrade ^a   Pereira, Leila M Meirelles ^a   Mandarim De Lacerda, C A ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Blood pressure; Enalapril; L NAME; Nitric oxide; Spontaneously hypertensive rats; Vascular remodeling

Indexed keywords

ANIMALIA;

ENALAPRIL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL; ARTICLE; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYMOLOGY; HEART; HEART MUSCLE; HYPERTENSION; MALE; METABOLISM; PATHOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; BLOOD PRESSURE; DRUG SYNERGISM; ENALAPRIL; HEART; HYPERTENSION; MALE; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, INBRED SHR;

EID: 0037686245     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2002.tb00458.x     Document Type: Article

References (62)

1. Pereira L.M.M., Mandarim-de-Lacerda C.A., Stereology of cardiac hypertrophy induced by NO blockade in rats treated with Enalapril and verapamil, Analyt. Quant. Cytol. Histol., 23: 330-338, 2001
2. Ito N., Nitta Y., Ohtani H., Ooshima A., Isyama S., Remodeling of microvessels by coronary hypertension of cardiac hypertrophy in rats, J. Mol. Cell. Cardiol., 26: 49-54, 1994
3. Mandarim-de-Lacerda C.A., Pereira L.M.M., Volume-weighted mean nuclear volume and numerical nuclear density in the cardiomyocyte following Enalapril and verapamil treatment, Virchows Arch., 438: 92-95, 2001
4. Pereira L.M.M., Mandarim-de-Lacerda C.A., Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade, Pathol. Res. Pract., 196: 305-311, 2000
5. Okamoto K., Aoki K., Development of a strain of spontaneously hypertensive rats, Japan Circ. J., 27: 282-293, 1963
6. Pinto Y.M., Paul M., Ganten D., Lesson from rat models of hypertension: from Goldblatt to genetic engineering, Cardiovasc. Res., 39: 77-88, 1998
7. Rothermund L., Paul M., Hypertension and the renin-angiotensin system: evidence from genetic and transgenic studies, Basic. Res. Cardiol., 93 (Suppl. 2): 1-6, 1998
8. Dogrell S.A., Brown L., Rat models of hypertension, cardiac hypertrophy and failure, Cardiovasc. Res., 39: 89-105, 1998
9. Folkow B., Early structural changes in hypertension: pathophysiology and clinical consequences, J. Cardiovasc. Pharmacol., 22 (Suppl. 1): 1-6, 1993
10. Olivetti G., Cigola E., Maestri R., Lagrasta C., Corradi D., Quaini F., Recent advances in cardiac hypertrophy, Cardiovasc. Res., 45: 68-75, 2000
11. Brunel P., Agabiti-Rosi E., Effects of angiotensin-converting enzyme inhibitors on the heart and vessels in clinical and experimental hypertension: a review, Clin. Drug. Invest., 12: 226-243, 1996
12. Furchgott R.F., Zawadski, J.V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcocholine, Nature, 288: 373-376, 1980
13. Palmer R.M.J., Ferrige A.G., Moncada S., Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor, Nature, 327: 524-526, 1987
14. Palmer R.M.J., Ashton D.S., Moncada S., Vascular endothelial cells synthesize nitric oxide from L-arginine, Nature, 333: 664-666, 1988
15. Buchwalow I.B., Schulze W., Karczewski P., Kostic M.M., Wallukat G., Morwinski R., Krause E.G., Müller J., Paul M., Slezak J., Luft F.C., Haller H., Inducible nitric oxide synthase in the myocardium, Mol. Cell. Biochem., 217: 73-82, 2001
16. Kone B. C., Molecular biology of natriuretic peptides and nitric oxide synthases, Cardiovasc. Res., 51: 429-441, 2001
17. Patel K.P., Li Y.F., Hirooka Y., Role of nitric oxide in central sympathetic outflow, Exp. Biol. Med., 226: 814-824, 2001
18. Mandarim-de-Lacerda C.A., Pereira L.M., Renal cortical remodelling by NO-synthesis blockers in rats is prevented by angiotensin-converting enzyme inhibitor and calcium channel blocker, J. Cell. Mol. Med., 5: 276-283, 2001
19. Matsubara B.B., Matsubara L.S., Zornoff L.A.M., Franco M., Janicki J.S., Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats, Basic Res. Cardiol. 93: 173-181, 1998
20. Weber K.T., Targeting pathological remodeling - concepts of cardioprotection and reparation, Circulation, 102: 1342-1345, 2000
21. Millatt L.J., Abdel-Rahman E.M., Siragy H.M., Angiotensin II and nitric oxide: a question of balance, Regulatory Peptides, 81: 1-10, 1999
22. Kahan T., The importance of left ventricular hypertrophy in human hypertension, J. Hypertens., 16: S23-S29, 1998
23. Frohlich E.D., Hypertension: evaluation and treatment, Williams & Wilkins, Baltimore, 1998
24. Bernátová I., Pecháòová O., Pelouch V., Šimko F., Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril, J. Mol. Cell. Cardiol., 32: 177-185, 2000
25. Brilla C.G., Renin-angiotensin-aldosterone system and myocardial fibrosis, Cardiovasc. Res., 47: 1-3, 2000
26. Mandarim-de-Lacerda C.A., What is the interest of normal and pathological morphological research to be quantitative? The example of the stereology, Braz. J. Morphol. Sci., 16: 131-139, 1999
27. Gundersen H.J.G., Jensen E.B., Stereological estimation of the volume-weighed mean volume of arbitrary particles observed in random sections, J. Microsc., 138: 127-142, 1985
28. Sørensen F.B., Stereological estimation of the mean and variance of nuclear volume from vertical sections, J. Microsc., 162: 203-229, 1991
29. Zar J.H., Biostatistical analysis, Prentice-Hall, Upper Saddle River, 1999
30. Cruz-Orive L.M., Weibel E.R., Recent stereological methods for cell biology: a brief survey, Am. J. Physiol., 258:148-L156, 1990
31. Pereira L.M.M., Mandarim-de-Lacerda C.A., Myocardial microcirculation stereological changes in rats subjected to nitric oxide synthesis inhibition, Pathol. Res. Pract., 195:177-181, 1999
32. Bernátová I., Pecháòová O., Šimko F., Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats, Physiol. Res., 45:311-316, 1996
33. Brilla C.G., Matsubara L., Weber K.T., Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-mediated regression of myocardial fibrosis, Hypertension, 28: 269-275, 1996
34. Numaguchi K., Egashira K., Takemoto M., Kadokami T., Shimokawa H., Sueishi K., Takeshita A., Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats, Hypertension, 26: 957-962, 1995
35. Takemoto M., Egashira K., Usui M., Numaguchi K., Tomita H., Tsutsui H., Shimokawa H., Sueishi K., Takeshita A., Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats, J. Clin. Invest., 99: 278-287, 1997
36. Weber K.T., Metabolic responses o extracellular matrix in tissue repair, Ann. Med., 29: 333-338, 1997
37. Bernátová I., Pecháòová O., Šimko F., Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney, Exp. Physiol., 84: 1095-1105, 1999
38. Šimko F., Šimko J., The potential role of nitric oxide in the hypertrophic growth of the left ventricle, Physiol. Res., 49: 37-46, 2000
39. Moreno H., Metze, Jr. K., Bento A.C., Antunes E., Zatz R., Nucci G., Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease, Bas. Res. Cardiol., 91: 248-255, 1996
40. Ono Y., Ono H., Matsuoka H., Fujimori T., Frohlich E.D., Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR, Hypertension, 34: 609-616, 1999
41. Matsuoka H., Nakata M., Keisuke Kohno, Koga Y., Nomura G., Toshima H., Imaizumi T., Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats, Hypertension, 27: 14-18, 1996
42. Chen P.Y., Sanders P.W., L-arginine abrogates salt-sensitive hypertension in Dahl Rapp rats, J. Clin. Invest., 88: 1559-1567, 1991
43. Pessanha M.G., Mandarim-de-Lacerda C.A., Hahn M.D., Stereology and immunohistochemistry of the myocardium in experimental hypertension: long-term and low dosage administration of inhibitor of the nitric oxide synthesis, Pathobiology, 67: 26-33, 1999
44. Pessanha M.G., Mandarim-de-Lacerda C.A., Influence of the chronic nitric oxide synthesis inhibition on cardiomyocytes number, Virchows Arch., 437: 667-674, 2000
45. Arnal J.F., Armani E.I., Chatellier G., Menard J., Michel J.B., Cardiac weight in hypertension induced by nitric oxide synthase blockade, Hypertension, 22: 380-387, 1993
46. Matsubara B.B., Matsubara L.S., Zornoff L.A.M., Franco M., Janicki J.S., Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats, Basic Res. Cardiol., 93: 173-181, 1998
47. Babál P., Pecháòová O., Berná tová I., Štvrtina S., Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia, Histol. Histopathol., 12: 623-629, 1997
48. Ono H., Ono Y., Frohlich E.D., Nitric oxide synthase inhibition in spontaneously hypertensive rats: systemic, renal, and glomerular hemodynamics, Hypertension, 26: 249-255, 1995
49. Saleh F.H., Jurjus A.R., A comparative study of morphological changes in spontaneously hypertensive rats and normotensive Wistar Kyoto rats treated with an angiotensin-converting enzyme inhibitor or a calcium-channel blocker, J. Pathol., 193: 415-420, 2001
50. Takemoto M., Egashira K., Usui M., Numaguchi K., Tomita H., Tsutsui H., Shimokawa H., Sueishi K., Takeshita A., Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats, J. Clin. Invest., 99: 278-287, 1997
51. Mandarim-de-Lacerda C.A., Pereira L.M.M., Numerical density of cardiomyocytes in chronic nitric oxide synthesis inhibition, Pathobiology, 68: 36-43, 2000
52. Moreno, Jr. H., Nathan L.P., Costa S.K.P., Metze K., Antunes E., Zatz R., De Nucci G., Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis, Eur. J. Pharmacol., 287: 93-96, 1995
53. Sládek T., Gerová M., Znojil V., Devát L., Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase, Physiol. Res., 45: 335-338, 1996
54. Bishop J.E., Lindahl G., Regulation of cardiovascular collagen synthesis by mechanical load, Cardiovasc. Res., 42: 27-44, 1999
55. Rakusan K., Cicutti N., Kazda S., Turek Z., Effect of nifedipine on coronary capillary geometry in normotensive and hypertensive rats, Hypertension, 24: 205-211, 1994
56. Moncada S., Nitric oxide in the vascular physiology and pathophysiology, Ann. N. Y. Acad. Sci., 811: 60-67, 1997
57. Black M.J., Bertram J.F., Johnston C.I., Effect of angiotensin-converting enzyme inhibition on myocardial vascularization in the adolescent and adult spontaneously hypertensive rat, J. Hypertens., 19: 785-794, 2001
58. Okruhlicová L., Tribulová N., Bernátová I., Pecháòová O., Induction of angiogenesis in NO-deficient rat heart, Physiol. Res., 49: 71-76, 2000
59. Forte P., Copland M., Smith L.M., Milne E., Sutherland J., Benjamin N., Basal nitric oxide synthesis in essential hypertension, Lancet, 349: 837-842, 1997
60. Clozel J.P., Kuhn H., Hefti F., Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension, J. Hypertens., 7: 267-275, 1989
61. Unger T., Mattfeldt T., Lamberty V., Bock P., Mall G., Linz W., Schülkens B.A., Gohlke P., Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries, Hypertension, 20: 478-482, 1992
62. Olivetti G., Cigola E., Lagrasta C., Ricci R., Quaini F., Monopoli A., Ongini E., Spirapril prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats, J. Cardiovasc. Pharmacol., 21: 362-370, 1993